Participants 140 230 4
patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial.
Participants 495 511 3
myeloma patients
Participants 785 954 8
There were 628 patients who were eligible for the clinical protocol E9486, but of these 521 were also entered on the companion laboratory study (E9487) and had CD19 data
